262 related articles for article (PubMed ID: 22028492)
21. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
22. A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors.
Fury MG; Sherman E; Haque S; Korte S; Lisa D; Shen R; Wu N; Pfister D
Cancer Chemother Pharmacol; 2012 Mar; 69(3):591-8. PubMed ID: 21913034
[TBL] [Abstract][Full Text] [Related]
23. Long-term survival in metastatic melanoma patients treated with sequential biochemotherapy: report of a Phase II study.
Neri B; Vannozzi L; Fulignati C; Pantaleo P; Pantalone D; Paoletti C; Perfetto F; Turrini M; Mazzanti R
Cancer Invest; 2006; 24(5):474-8. PubMed ID: 16939954
[TBL] [Abstract][Full Text] [Related]
24. Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.
Weber JS; Zarour H; Redman B; Trefzer U; O'Day S; van den Eertwegh AJ; Marshall E; Wagner S
Cancer; 2009 Sep; 115(17):3944-54. PubMed ID: 19536884
[TBL] [Abstract][Full Text] [Related]
25. Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses.
Weide B; Eigentler TK; Pflugfelder A; Zelba H; Martens A; Pawelec G; Giovannoni L; Ruffini PA; Elia G; Neri D; Gutzmer R; Becker JC; Garbe C
Cancer Immunol Res; 2014 Jul; 2(7):668-78. PubMed ID: 24906352
[TBL] [Abstract][Full Text] [Related]
26. A prospective single arm phase II study of dacarbazine and treosulfan as first-line therapy in metastatic uveal melanoma.
O'Neill PA; Butt M; Eswar CV; Gillis P; Marshall E
Melanoma Res; 2006 Jun; 16(3):245-8. PubMed ID: 16718271
[TBL] [Abstract][Full Text] [Related]
27. Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study.
Agarwala SS; Kirkwood JM
Cancer; 2003 Jan; 97(1):121-7. PubMed ID: 12491513
[TBL] [Abstract][Full Text] [Related]
28. A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients.
Weide B; Eigentler T; Catania C; Ascierto PA; Cascinu S; Becker JC; Hauschild A; Romanini A; Danielli R; Dummer R; Trefzer U; Elia G; Neri D; Garbe C
Cancer Immunol Immunother; 2019 Sep; 68(9):1547-1559. PubMed ID: 31482307
[TBL] [Abstract][Full Text] [Related]
29. The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer.
Catania C; Maur M; Berardi R; Rocca A; Giacomo AM; Spitaleri G; Masini C; Pierantoni C; González-Iglesias R; Zigon G; Tasciotti A; Giovannoni L; Lovato V; Elia G; Menssen HD; Neri D; Cascinu S; Conte PF; Braud Fd
Cell Adh Migr; 2015; 9(1-2):14-21. PubMed ID: 25562532
[TBL] [Abstract][Full Text] [Related]
30. Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study.
Danielli R; Patuzzo R; Di Giacomo AM; Gallino G; Maurichi A; Di Florio A; Cutaia O; Lazzeri A; Fazio C; Miracco C; Giovannoni L; Elia G; Neri D; Maio M; Santinami M
Cancer Immunol Immunother; 2015 Aug; 64(8):999-1009. PubMed ID: 25971540
[TBL] [Abstract][Full Text] [Related]
31. Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts.
Orecchia P; Conte R; Balza E; Pietra G; Mingari MC; Carnemolla B
Oncotarget; 2015 Nov; 6(35):37426-42. PubMed ID: 26460958
[TBL] [Abstract][Full Text] [Related]
32. Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial.
Lieverse RIY; Van Limbergen EJ; Oberije CJG; Troost EGC; Hadrup SR; Dingemans AC; Hendriks LEL; Eckert F; Hiley C; Dooms C; Lievens Y; de Jong MC; Bussink J; Geets X; Valentini V; Elia G; Neri D; Billiet C; Abdollahi A; Pasquier D; Boisselier P; Yaromina A; De Ruysscher D; Dubois LJ; Lambin P
BMC Cancer; 2020 Jun; 20(1):557. PubMed ID: 32539805
[TBL] [Abstract][Full Text] [Related]
33. Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma: a phase II study.
Ferrucci PF; Minchella I; Mosconi M; Gandini S; Verrecchia F; Cocorocchio E; Passoni C; Pari C; Testori A; Coco P; Munzone E
Melanoma Res; 2015 Jun; 25(3):239-45. PubMed ID: 25746039
[TBL] [Abstract][Full Text] [Related]
34. Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium.
Hainsworth JD; Infante JR; Spigel DR; Peyton JD; Thompson DS; Lane CM; Clark BL; Rubin MS; Trent DF; Burris HA
Cancer; 2010 Sep; 116(17):4122-9. PubMed ID: 20564157
[TBL] [Abstract][Full Text] [Related]
35. The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF.
Schwager K; Hemmerle T; Aebischer D; Neri D
J Invest Dermatol; 2013 Mar; 133(3):751-758. PubMed ID: 23096716
[TBL] [Abstract][Full Text] [Related]
36. A phase II trial of high-dose cisplatin and dacarbazine. Lack of efficacy of high-dose, cisplatin-based therapy for metastatic melanoma.
Steffens TA; Bajorin DF; Chapman PB; Lovett DR; Cody-Johnson BV; Templeton MA; Heelan RT; Wong GY; Portlock CS; Oettgen HF
Cancer; 1991 Sep; 68(6):1230-7. PubMed ID: 1873774
[TBL] [Abstract][Full Text] [Related]
37. Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: a multicenter phase II study.
Stoter G; Aamdal S; Rodenhuis S; Cleton FJ; Iacobelli S; Franks CR; Oskam R; Shiloni E
J Clin Oncol; 1991 Sep; 9(9):1687-91. PubMed ID: 1875225
[TBL] [Abstract][Full Text] [Related]
38. Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy.
Pretto F; Elia G; Castioni N; Neri D
Cancer Immunol Immunother; 2014 Sep; 63(9):901-10. PubMed ID: 24893857
[TBL] [Abstract][Full Text] [Related]
39. Chemosensitisation of malignant melanoma by BCL2 antisense therapy.
Jansen B; Wacheck V; Heere-Ress E; Schlagbauer-Wadl H; Hoeller C; Lucas T; Hoermann M; Hollenstein U; Wolff K; Pehamberger H
Lancet; 2000 Nov; 356(9243):1728-33. PubMed ID: 11095261
[TBL] [Abstract][Full Text] [Related]
40. A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma.
Kirkwood JM; Gonzalez R; Reintgen D; Clingan PR; McWilliams RR; de Alwis DP; Zimmermann A; Brown MP; Ilaria RL; Millward MJ
Cancer; 2011 Oct; 117(20):4732-9. PubMed ID: 21456002
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
